RT Journal Article SR Electronic T1 Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer’s disease JF Journal of Neurology, Neurosurgery & Psychiatry JO J Neurol Neurosurg Psychiatry FD BMJ Publishing Group Ltd SP 796 OP 803 DO 10.1136/jnnp-2024-333468 VO 95 IS 9 A1 Dobson, Ruth A1 Patterson, Katherine A1 Malik, Reshad A1 Mandal, Uttara A1 Asif, Hina A1 Humphreys, Ros A1 Payne, Michael A1 O-Charoenrat, Eng A1 Huzzey, Lauren A1 Clare, Adam A1 Green, Kate A1 Morton, Maija A1 Sohrabi, Catrin A1 Singh, Navreen A1 Pasupathy, Amirtha A1 Patel, Milan A1 Whiteman, Sam A1 Maxmin, Kate A1 Bass, Nicholas A1 Gupta, Bhavya A1 Cooper, Claudia A1 Marshall, Charles A1 Weil, Rimona Sharon A1 Mummery, Catherine J YR 2024 UL http://jnnp.bmj.com/content/95/9/796.abstract AB Background Disease-modifying therapies (DMTs) for Alzheimer’s disease (AD) have early evidence of efficacy. Widespread delivery of DMTs will require major service reconfiguration. Treatment pathways will need to include triaging for eligibility, regular infusions and baseline and follow-up MRI scanning. A critical step in planning is provision of real-world estimates of patients likely to be eligible for triaging, but these are challenging to obtain.Methods We performed a retrospective service evaluation of patients attending five memory services across North and East London and a national specialist cognitive disorders service. We examined the likely proportion of patients who would (1) be referred for triaging for DMTs and (2) potentially be suitable for treatments.Results Data from a total of 1017 patients were included, 517 of whom were seen in community memory services and 500 in a specialist clinic. In the memory services, 367/517 (71%) were diagnosed with possible AD. After exclusions of those in whom cognitive and frailty scores, MRI contraindications or anticoagulant use indicated they would be unlikely to be suitable, an estimated 32% would be eligible for triaging. In the specialist cognitive clinic, where additional investigations are available, 14% of those seen (70/500) would be potentially eligible for treatment.Conclusions While a sizeable proportion of patients attending memory clinics may be referred for triaging for DMTs for AD, only a minority are likely to be suitable for these, as demonstrated in patients seen in specialist cognitive services. This will need to be considered when designing pathways for DMT delivery.